Kerendia (finerenone tablets – Bayer) — Cigna

Chronic Kidney Disease in a Patient with Type 2 Diabetes

Initial criteria

Patient is age ≥ 18 years; AND
Patient has a diagnosis of type 2 diabetes; AND
Patient meets ONE of the following (a or b):
a) Patient is currently receiving a maximally tolerated labeled dosage of an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB); OR
b) According to the prescriber, the patient has a contraindication or has experienced significant intolerance to ACE inhibitor and ARB therapy; AND
At baseline (prior to the initiation of Kerendia), patient meets ALL of the following (a, b, and c):
a) Estimated glomerular filtration rate ≥ 25 mL/min/1.73 m2; AND
b) Urine albumin-to-creatinine ratio ≥ 30 mg/g; AND
c) Serum potassium level ≤ 5.0 mEq/L

Patient is age ≥ 18 years; AND
Patient has a diagnosis of type 2 diabetes; AND
Patient meets ONE of the following (a or b):
a) Patient is currently receiving a maximally tolerated labeled dosage of an angiotensin converting enzyme (ACE) inhibitor or angiotensin receptor blocker (ARB); OR
b) According to the prescriber, the patient has a contraindication or has experienced significant intolerance to ACE inhibitor and ARB therapy.

1 year